Stranded in Kuwait, Indian expat finally reunites with his family in DK thanks to ISF

Bengaluru, May 13: The Karnataka Common Entrance Test (K-CET) 2020 will be held on July 30 and 31.

The test, earlier as scheduled to be held on April 22, 23 and 24, was postponed due to COVID-19 crisis and the nation-wide lockdown.

Now, considering the dates for National Eligibility cum Entrance Test (NEET) and Joint Entrance Examination (JEE) dates announced by the Union government, the state government has announced the revised dates on Wednesday.

Higher Education Minister Dr C N Ashwath Narayan announced this in a press conference. The test will be held online, the minister said. 

For CET 2020, over 1.90 lakh students registered for admission to undergraduate engineering, B Tech, Architecture, Agriculture and veterinary science courses.

Home quarantine for repatriated pregnant women, children, senior citizens if they test covid-19 negative 

The Union Health Ministry has revised its discharge guidelines for COVID-19 patients, stating that only those with severe illness need to be tested (through a swab test) and a negative report needs to be obtained before discharge.

The latest guideline adds that other categories of patients, including very mild, mild, pre-symptomatic and moderate cases, need not be tested before discharge.

Kalaburagi, Apr 20: With no COVID-19 case reported here on Sunday, the total number of virus-infected people in the district stood at 22.

While three persons have succumbed to the infection in the district so far, three others have been cured and discharged.

"No COVID-19 case was reported in Kalaburagi district today. Total 22 positive cases and 3 deaths have been reported in the district till date. Three persons have been cured," said District Magistrate B. Sharat.

Karnataka's total count of coronavirus patients has surged to 390, said the State Health Department on Sunday.

"Six new cases have been confirmed for COVID-19 in the State from 5 pm on Saturday till 5 pm on Sunday. Cumulatively, 390 COVID-19 positive cases have been confirmed in the state," it said.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.